2022
Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison
Wolff H, Qendri V, Kunst N, Alarid-Escudero F, Coupé V. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison. Medical Decision Making 2022, 42: 956-968. PMID: 35587181, PMCID: PMC9452448, DOI: 10.1177/0272989x221100112.Peer-Reviewed Original ResearchConceptsCost-effectiveness acceptability curvesCost-effectiveness acceptability frontierCost-effectiveness analysisImpact of uncertaintyAcceptability curvesDecision analytic modelWrong decisionsCost-effectiveness comparisonBenefit curvePolicy makersHeat mapDecision makersPotential lossIntegration of methodsDecisionsIntegration of informationDecision problemMakersOverview of methodsUncertaintyHealth policyType of informationCourse of actionRelevant informationUse toolEmerging Therapies for COVID-19: The Value of Information From More Clinical Trials
Dijk SW, Krijkamp EM, Kunst N, Gross CP, Wong JB, Hunink MGM. Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. Value In Health 2022, 25: 1268-1280. PMID: 35490085, PMCID: PMC9045876, DOI: 10.1016/j.jval.2022.03.016.Peer-Reviewed Original ResearchConceptsCohort state-transition modelUS healthcare perspectiveValue of informationFace of uncertaintyQALY willingnessPolicy makersLifetime horizonHealthcare perspectiveState transition modelInformation analysisImmediate approvalModel outcomesImplementation decisionsOptimal momentWillingnessPolicyMakersMost valueCOVID-19DecisionsCostHorizonFurther researchAdditional evidenceUncertaintyCost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia. American Journal Of Hematology 2022, 98: 122-130. PMID: 35147241, PMCID: PMC9365880, DOI: 10.1002/ajh.26497.Peer-Reviewed Original ResearchMeSH KeywordsAdultCost-Benefit AnalysisHumansProspective StudiesPurpura, Thrombocytopenic, IdiopathicRituximabSplenectomyThrombopoietinConceptsThrombopoietin receptor agonistsChronic immune thrombocytopeniaSecond-line therapyImmune thrombocytopeniaEarly useCurrent practice trendsProbabilistic sensitivity analysesCost-effective treatmentFirst cost-effectiveness analysisCost-effectiveness analysisU.S. health systemLack of evidenceEarly splenectomyHematology (ASH) guidelinesReceptor agonistCurrent guidelinesSplenectomyClinical practicePractice trendsTherapyHealth systemCost-effective strategyRituximabThrombocytopeniaAmerican SocietyPopulation-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research
Kunst N, Stout N, O’Brien G, Christensen K, McMahon P, Wu A, Diller L, Yeh J. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. Journal Of The National Cancer Institute 2022, 114: 722-731. PMID: 35043946, PMCID: PMC9086756, DOI: 10.1093/jnci/djac013.Peer-Reviewed Original ResearchConceptsUsual careClinical benefitTP53 variantsIncremental cost-effectiveness ratioPathogenic TP53 variantsCancer-related deathGermline TP53 variantsUS birth cohortPotential health outcomesCost-effectiveness ratioIdentification of childrenTumor surveillanceClinical studiesRhabdomyosarcoma casesPediatric cancerEarly cancer detectionRoutine surveillanceBirth cohortHealth outcomesAge 20Newborn screeningMalignancy detectionFurther researchCareTP53
2021
Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial
Heath A, Strong M, Glynn D, Kunst N, Welton N, Goldhaber-Fiebert J. Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial. Medical Decision Making 2021, 42: 143-155. PMID: 34388954, PMCID: PMC8793320, DOI: 10.1177/0272989x211026292.Peer-Reviewed Original ResearchEarly Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers
Jongeneel G, Greuter M, Kunst N, van Erning F, Koopman M, Medema J, Vermeulen L, Ijzermans J, Vink G, Punt C, Coupé V. Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 1726-1734. PMID: 34162659, PMCID: PMC7611620, DOI: 10.1158/1055-9965.epi-21-0078.Peer-Reviewed Original ResearchMeSH KeywordsChemotherapy, AdjuvantColonic NeoplasmsCost-Benefit AnalysisHumansMarkov ChainsNeoplasm StagingNetherlandsQuality-Adjusted Life YearsRisk AssessmentConceptsConsensus molecular subtypesStage II colon cancerGuideline strategyEarly cost-effectiveness analysisColon cancer deathsPrognostic molecular markersMarkov cohort modelDutch societal perspectiveCancer treatment selectionCost-effectiveness analysisAdjuvant chemotherapyAdjuvant treatmentCancer deathCost-effectiveness assessmentMolecular subtypesTreatment selectionCurrent evidenceColon cancerSocietal perspectiveDecision uncertaintyMolecular markersCohort modelPatientsMarkersVOI analysisA Review of Web-Based Tools for Value-of-Information Analysis
Tuffaha H, Rothery C, Kunst N, Jackson C, Strong M, Birch S. A Review of Web-Based Tools for Value-of-Information Analysis. Applied Health Economics And Health Policy 2021, 19: 645-651. PMID: 34046866, PMCID: PMC7613968, DOI: 10.1007/s40258-021-00662-4.Peer-Reviewed Original ResearchUnderstanding Regional Variation in the Cost of Breast Cancer Screening Among Privately Insured Women in the United States
Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Lindau ST, Richman IB, Gross CP. Understanding Regional Variation in the Cost of Breast Cancer Screening Among Privately Insured Women in the United States. Medical Care 2021, 59: 437-443. PMID: 33560712, PMCID: PMC8611614, DOI: 10.1097/mlr.0000000000001506.Peer-Reviewed Original Research
2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. PatientsPerspective and Costing in Cost-Effectiveness Analysis, 1974–2018
Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018. PharmacoEconomics 2020, 38: 1135-1145. PMID: 32696192, PMCID: PMC7373843, DOI: 10.1007/s40273-020-00942-2.Peer-Reviewed Original ResearchCalculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies
Heath A, Kunst N, Jackson C, Strong M, Alarid-Escudero F, Goldhaber-Fiebert JD, Baio G, Menzies NA, Jalal H. Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies. Medical Decision Making 2020, 40: 314-326. PMID: 32297840, PMCID: PMC7968749, DOI: 10.1177/0272989x20912402.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesCost-Benefit AnalysisData AccuracyHumansModels, EconomicMonte Carlo MethodConceptsHealth economic modelApproximation methodEconomic modelTraditional Monte Carlo methodTraditional Monte CarloMonte Carlo algorithmMonte Carlo methodHigh computational burdenSample informationCarlo algorithmData generation processCarlo methodMonte CarloComputational burdenComputational speedPolicy decisionsComplex decision modelsComputation methodDecision modelRealistic exampleSample sizeEVSIDifferent examplesExpected valuesCarlo
2019
A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management
Kunst NR, Alarid-Escudero F, Paltiel AD, Wang SY. A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management. Value In Health 2019, 22: 1102-1110. PMID: 31563252, PMCID: PMC7343670, DOI: 10.1016/j.jval.2019.05.004.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerObservational studyBreast cancerLow-risk early-stage breast cancerHormone receptor-positive early-stage breast cancerPredictive valueLow-risk womenProspective observational studyHigh-risk womenRetrospective observational studyBreast cancer managementQuality-adjusted life yearsCost-effectiveness findingsTraditional risk predictionAdjuvant chemotherapyChemotherapy useAlternative study designsOncotype DXCancer managementClinical utilityCurrent evidenceInsufficient evidenceLife yearsRoutine useStudy design
2018
Cost-effectiveness of diagnostic algorithms for peanut allergy in children
Kunst NR, Lindvik H, Carlsen KH, Håland G, Jørgensen E, Lødrup Carlsen KC. Cost-effectiveness of diagnostic algorithms for peanut allergy in children. Journal Of Allergy And Clinical Immunology 2018, 143: 1243-1246. PMID: 30445059, DOI: 10.1016/j.jaci.2018.10.050.Peer-Reviewed Original Research